Tandem Meetings – 2024 – Encore Poster Presentation 293
Publications
February 22, 2024
Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33ALLO) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation (Trial in Progress)
VCAR33
Presented by: Nirali N. Shah, MD, MHSc – National Cancer Institute | National Institutes of Health